Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Research Tools and Instruments - Category 1 (<$150,000)

Carleton University

$61,362.00

Multiplex-ing our way to the future: advanced technology for metabolic analysis

FY 2012-13

Summary
Analytical technologies in biology constantly improve but sometimes a ""quantum leap"" takes place that forever changes how molecular science is done. One such leap occurred a few years ago with the introduction of multiplex technology, first commercialized by Luminex Corp. In this procedure, samples are mixed with a suspension of microspheres internally labeled with a distinct combination of fluorescent dyes. With up to 100 distinct signatures, each microsphere is coated by a different capture ligand that binds to a specific target analyte. After target capture (and secondary labeling of the captured analyte), the beads are analyzed by flow cytometry whereby dual laser light identifies both the microsphere and quantifies the amount of captured analyte. This technology has revolutionized high-throughput analysis/screening in the field of genomics and proteomics, and is adaptable to quantification of hundreds of target types/actions: proteins, post-translational modifications to proteins, DNA, messenger RNA, microRNA, transcription factor binding to DNA, etc. Key advantages of the approach include consistency and speed of analysis, need for only very tiny sample sizes, and quantification of multiple related analytes within a single sample, frequently providing a ""snapshot"" of the relative responses of multiple components of a cellular pathway or process. The current application requests the purchase of a Luminex 200 system, a medium cost instrument that has the flexibility to use both the polystyrene and magnetic bead technologies to give users maximum choices of commercial or custom kits. The instrument will serve the diverse research programs of three laboratories - biochemistry of animal adaptation to environmental stress (Storey, Biochemistry), molecular mechanisms of Parkinson's disease and depression (Hayley, Neuroscience), and genomic research in a yeast model to identify/investigate novel genes/proteins that regulate protein translation (Golshani, Biology) while also providing a unique facility within the Faculty of Science at Carleton University. The instrument will optimize, maximize and fundamentally change our research approach going forward over the next decade.
Program
Research Tools and Instruments - Category 1 (<$150,000)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
439698-2013
Name nom
Storey, Kenneth
Department département
Biology
Organization id
23
Institution établissement
Carleton University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2013
Award amount
61362
Program id
EQPEQ
Program name en
Research Tools and Instruments - Category 1 (<$150,000)
Program name fr
Outils et instruments de recherche - catégorie 1 (<150 000$)
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5504
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Animal physiology and metabolism
Research subject fr
Physiologie et métabolisme des animaux
Partie
1
Nb partie
1
Application title
Multiplex-ing our way to the future: advanced technology for metabolic analysis
Keyword
NSERC
Application summary
Analytical technologies in biology constantly improve but sometimes a ""quantum leap"" takes place that forever changes how molecular science is done. One such leap occurred a few years ago with the introduction of multiplex technology, first commercialized by Luminex Corp. In this procedure, samples are mixed with a suspension of microspheres internally labeled with a distinct combination of fluorescent dyes. With up to 100 distinct signatures, each microsphere is coated by a different capture ligand that binds to a specific target analyte. After target capture (and secondary labeling of the captured analyte), the beads are analyzed by flow cytometry whereby dual laser light identifies both the microsphere and quantifies the amount of captured analyte. This technology has revolutionized high-throughput analysis/screening in the field of genomics and proteomics, and is adaptable to quantification of hundreds of target types/actions: proteins, post-translational modifications to proteins, DNA, messenger RNA, microRNA, transcription factor binding to DNA, etc. Key advantages of the approach include consistency and speed of analysis, need for only very tiny sample sizes, and quantification of multiple related analytes within a single sample, frequently providing a ""snapshot"" of the relative responses of multiple components of a cellular pathway or process. The current application requests the purchase of a Luminex 200 system, a medium cost instrument that has the flexibility to use both the polystyrene and magnetic bead technologies to give users maximum choices of commercial or custom kits. The instrument will serve the diverse research programs of three laboratories - biochemistry of animal adaptation to environmental stress (Storey, Biochemistry), molecular mechanisms of Parkinson's disease and depression (Hayley, Neuroscience), and genomic research in a yeast model to identify/investigate novel genes/proteins that regulate protein translation (Golshani, Biology) while also providing a unique facility within the Faculty of Science at Carleton University. The instrument will optimize, maximize and fundamentally change our research approach going forward over the next decade.